Kiadis Pharma commences enrollment in multinational ATIR study News-Medical-Net Mon, 30 Nov 2009 06:00 AM PST Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an ... | Allos Therapeutics granted U.S. patent for FOLOTYN News-Medical-Net Mon, 30 Nov 2009 05:45 AM PST Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN⢠(pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025. | Immunomedics to Present at 51st ASH Annual Meeting GlobeNewswire via Yahoo! Finance Mon, 30 Nov 2009 05:30 AM PST MORRIS PLAINS, N.J. -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that nine presentations involving its product candidates will be given at the 51st American Society of Hematology Annual Meeting, scheduled for December 5 - 8, 2009, in New Orleans, LA. | Volleyball fundraiser for breast cancer Queens Courier Mon, 30 Nov 2009 05:28 AM PST Cardozo and Francis Lewis High School put their rivalry on hold and âwent pinkâ for a volleyball match to raise money for breast cancer awareness. | First live targeting of tumors with RNA-based technology EurekAlert! Mon, 30 Nov 2009 05:27 AM PST ( Duke University Medical Center ) Researchers at Duke University Medical Center have devised a way they might deliver the right therapy directly to tumors using special molecules, called aptamers, which specifically bind to living tumor tissue. They screened a large pool of aptamers in a rodent with liver cancer until they found the best molecule to bind to a tumor protein. | Kangaroo clue to skin cancer cure The Age Mon, 30 Nov 2009 05:17 AM PST Australia has one of the world's highest skin-cancer rates, but researchers think the key to reducing it could lie with the kangaroo. | | |
|
No comments:
Post a Comment